Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

Gastroenterology - 1 Aug 2014

McGivern David R, Masaki Takahiro, Williford Sara, Ingravallo Paul, Feng Zongdi, Lahser Frederick, Asante-Appiah Ernest, Neddermann Petra, De Francesco Raffaele, Howe Anita Y, Lemon Stanley M

Abstract excerpt

BACKGROUND & AIMS: All-oral regimens combining different classes of direct-acting antivirals (DAA) are highly effective for treatment of patients with chronic hepatitis C. NS5A inhibitors will likely form a component of future interferon-sparing treatment regimens. However, despite their potentia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Virus Assembly
Share to Virus Replication
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Enzyme Inhibitors

Share to Hepacivirus

Share to Protease Inhibitors

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24768676
DOI: 10.1053/j.gastro.2014.04.021
PMCID: PMC4107048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24768676-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.PMID 24768676Read ↗

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeSemantic proximity Read ↗

Mathematical modeling of plus-strand RNA virus replication to identify broad-spectrum antiviral treatment strategiesSemantic proximity Read ↗

Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein MechanismsSemantic proximity Read ↗

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.Semantic proximity Read ↗

Quantitative modeling of SARS-CoV-2 replication reveals phase-specific bottlenecks and antiviral targetsSemantic proximity Read ↗

Disentangling the lifespans of hepatitis C virus-infected cells and intracellular vRNA replication-complexes during direct-acting anti-viral therapy.Semantic proximity Read ↗

Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.Semantic proximity Read ↗

Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replicationSemantic proximity Read ↗

Hepatitis C virus NS5A inhibitor daclatasvir allosterically impairs NS4B-involved protein-protein interactions within the viral replicase and disrupts the replicase quaternary structure in a replicase assembly surrogate systemSemantic proximity Read ↗

Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.Semantic proximity Read ↗

Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.Semantic proximity Read ↗

The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.